March 11, 2024- Thermo Fisher Scientific Inc. announced the launch of a new CorEvitas syndicated clinical registry in generalized pustular psoriasis (GPP). This registry, which is open to enrollment, is CorEvitas’ 10th syndicated disease registry and addresses an unmet need for real-world evidence (RWE) related to the clinical and patient-reported outcomes of patients with GPP.
The new registry will prospectively collect detailed patient-level data enabling assessment of the natural history of the disease and treatment patterns, along with the prevalence and incidence of comorbidities in patients with the disease. Granular, longitudinal outcome measures will be collected during registry visits, some of which include clinician-reported GPP outcomes, lab measures and treatment history, as well as patient-reported outcomes assessing symptom impact and quality of life. Drug safety data also will be collected, including serious adverse events and other adverse events of special interest.